News & Events

Disc Medicine Expands Pipeline Focused on Hepcidin Pathway

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies

Cambridge, Mass. – October 29, 2019 – Disc Medicine, a hematology company that is applying new insights in hepcidin biology to develop therapies addressing ineffective red blood cell production in hematologic diseases, today announced that it has entered into an exclusive license agreement with AbbVie for the worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies. Terms of the license agreement have not been disclosed.

“The addition of these hemojuvelin antagonist antibodies to our pipeline is an excellent strategic fit for Disc Medicine,” said Brian MacDonald, founder and interim CEO of Disc Medicine. “Our first program is a novel, orally administered therapy which increases hepcidin expression to treat iron loading anemias. In contrast, these antibodies target hemojuvelin to reduce hepcidin expression and provide us with the opportunity to develop new approaches to the treatment of anemia in a different spectrum of chronic inflammatory and hematologic diseases.”

Hepcidin, a small peptide hormone produced in the liver, is the key regulator of iron metabolism that when dysregulated is associated with either iron overload or iron deficiency.  Both of these conditions can be associated with ineffective red blood cell production, often leading to severe anemia in a range of hematological and non-hematological diseases that can significantly impact lifespan as well as quality of life.

About Disc Medicine

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

Media Contact

Arleen Goldenberg
Verge Scientific Communications
agoldenberg@vergescientific.com
Phone: 917-548-1582

More News

Disc Medicine Expands Leadership T…

Jonathan Yu Named Senior Vice President of Corporate Strategy
William Savage, MD, PhD Appointed Vice President of Clinical Development

read more

John Quisel, JD, PhD Joins Disc Me…

Cambridge, Mass. – January 28, 2020 – Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red…

read more

Disc Medicine Completes $50 Millio…

Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic dise…

read more

Disc Medicine Expands Pipeline Foc…

Enters into exclusive agreement with AbbVie for series of Hemojuvelin Antagonist Monoclonal Antibodies Cambridge, Mass. – October 29, 2019 – Disc Medicin…

read more

Introducing Disc Medicine, a New H…

Introducing Disc Medicine – we are a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell productions (eryt…

read more